Entropy Technologies LP Buys Shares of 10,067 LivaNova PLC (NASDAQ:LIVN)

Entropy Technologies LP purchased a new position in LivaNova PLC (NASDAQ:LIVN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,067 shares of the company’s stock, valued at approximately $529,000.

A number of other hedge funds have also recently made changes to their positions in LIVN. Fifth Third Bancorp boosted its stake in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares in the last quarter. Hexagon Capital Partners LLC lifted its stake in shares of LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after buying an additional 370 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of LivaNova during the first quarter valued at approximately $84,000. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova during the second quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC purchased a new position in LivaNova in the 1st quarter worth approximately $94,000. 97.64% of the stock is owned by institutional investors.

LivaNova Trading Down 0.4 %

Shares of NASDAQ:LIVN opened at $52.10 on Friday. The stock’s 50-day simple moving average is $51.67 and its two-hundred day simple moving average is $52.98. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of 124.05 and a beta of 1.01. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Analyst Ratings Changes

Several analysts have commented on LIVN shares. Robert W. Baird increased their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price objective on the stock. Mizuho decreased their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.